TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
PEPG

PepGen Ltd

Healthcare · Biotechnology

2.70$ -1.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

PepGen Ltd (PEPG) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 141 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet PEPG
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– – – 11 – 20 149 144 132 231 208 217 201 182 164 143 207 194 170 151 127 102 190 174 156 141
– – – 10 9.8 19 147 140 126 226 204 186 168 150 133 113 178 165 142 124 101 77 166 151 134 120
– – – 9.8 -9.8 16 142 133 119 219 196 182 165 147 130 81 134 66 42 49 44 35 143 61 42 23
– – – 9.8 9.8 16 142 133 119 219 196 182 165 147 130 110 175 161 139 120 98 75 164 148 132 117
– – – 0.4 0.8 0.8 4.0 4.7 4.6 4.2 3.9 0.1 – – – – – – – – – – – – – –
– – – – – – – – -2.2 -3.4 -4.6 – – – – – – – – – – – – – – –
– – – – 0.6 0.6 0.6 0.6 2.6 2.8 2.7 3.3 5.3 30 – – – – – – – – – – – –
– – – 0.9 – 5.2 9.5 11 16 21 16 38 36 35 38 35 28 38 33 32 36 31 27 26 22 22
– – – 0.8 5.2 5.2 9.2 10 16 21 16 19 18 17 21 18 11 22 17 17 20 16 13 13 9.0 9.0
– – – – – – – – – – – 5.6 3.7 3.5 3.0 3.0 3.0 3.0 3.1 3.1 3.1 3.1 3.2 3.2 3.2 3.2
– – – 0.7 1.9 1.9 1.2 3.2 1.9 5.4 4.6 1.4 1.5 1.8 4.0 1.0 1.5 7.7 5.9 1.8 2.7 0.9 0.8 0.8 0.6 1.1
– – – 9.8 9.8 14 140 133 116 210 193 180 165 147 126 108 179 155 137 119 92 71 163 147 134 120
– – – -6.5 -18 -18 -27 -34 -52 -69 -88 -103 -119 -139 -162 -181 -200 -228 -249 -271 -302 -325 -343 -361 -379 -397
0.9 0.9 22 22 22 22 22 22 21 22 24 24 24 24 24 24 29 32 33 33 33 33 33 42 69 69

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?